The diagnostic value and pathogenetic role of lncRNA-ATB in patients with osteoarthritis

BACKGROUND: In view of the roles of long non-coding RNAs (lncRNAs) in human diseases and the high incidence of osteoarthritis, we investigated the role of long non-coding RNA activated by transforming growth factor-β (lncRNA-ATB) in osteoarthritis and explored its diagnostic value for this disease. METHODS: The study involved 98 patients with osteoarthritis and 76 healthy subjects. Blood was extracted from each participant and the expression of lncRNA-ATB in the serum was detected using quantitative Real Time -PCR. ROC curve analysis was performed to evaluate the diagnostic value of lncRNA-ATB for osteoarthritis. Based on the median serum level of lncRNA-ATB, patients were divided into a high-level group and a low-level group. Correlations between the serum levels of lncRNA-ATB and basic information about the patients were analyzed using the chi-square test. LncRNA-ATB overexpression in human chondrocyte cell line CHON-001 (ATCC CRL-2846) was established to study the effects on chondrocyte proliferation (using the CCK-8 assay) and viability. RESULTS: LncRNA-ATB expression was significantly downregulated in the serum of osteoarthritis patients compared with the healthy controls, meaning this downregulation effectively distinguished osteoarthritis patients from healthy subjects. LncRNA-ATB expression in the serum was not significantly affected by the patients’ gender, age or habits, including smoking and alcohol consumption. LncRNA-ATB overexpression activated Akt signaling, promoted proliferation and increased the viability of the chondrocytes. CONCLUSION: We conclude that downregulation of lncRNA-ATB in serum is a reliable diagnostic marker for osteoarthritis and that this lncRNA participates in the pathogenesis of osteoarthritis by regulating the proliferation and viability of chondrocytes through the activation of Akt signaling. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s11658-018-0118-9) contains supplementary material, which is available to authorized users.